NCT06129500

Brief Summary

The goal of this case series is to explore whether a talking therapy, specifically Cognitive Behavioural Therapy (CBT) is acceptable and feasible in the management of mood-driven impulsive behaviours in people with bipolar disorder (BD). The main questions it aims to answer are:

  • Whether CBT Is a feasible intervention for participants with BD who report mood-driven, problematic impulsive behaviours.
  • Whether CBT for mood-driven, problematic impulsive behaviours (CBT-PIB) is acceptable to service users with BD and therapists.
  • Whether clinical outcomes are consistent with the potential for this novel intervention to offer clinical benefit to participants with BD. The study also hopes to:
  • conduct a preliminary examination of the safety of CBT-PIB and the research procedures.
  • gather information on the potential mechanisms of action of CBT-PIB and,
  • gather information on the types of mood-driven impulsive behaviours individuals with BD may seek support for. Participants will:
  • be offered up to 12 individual sessions of CBT focusing on mood-driven impulsive behaviours.
  • be asked to complete a battery of self-report measures (5) when they enter the study and at the start and end of treatment.
  • be asked to track mood and impulsive behaviours by completing a brief set of measures (3) weekly during the two-week baseline phase, the intervention phase and the 2-week post-intervention phase.
  • be asked to complete a survey on the acceptability of the intervention and
  • be invited to an optional semi-structured interview on their research experience.

Trial Health

53
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial recruitment is currently suspended
Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
9mo left

Started Aug 2023

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
suspended

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress79%
Aug 2023Jan 2027

Study Start

First participant enrolled

August 17, 2023

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

October 26, 2023

Completed
18 days until next milestone

First Posted

Study publicly available on registry

November 13, 2023

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 10, 2026

Expected
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 24, 2027

Last Updated

April 30, 2025

Status Verified

April 1, 2025

Enrollment Period

3.1 years

First QC Date

October 26, 2023

Last Update Submit

April 25, 2025

Conditions

Outcome Measures

Primary Outcomes (5)

  • Overall acceptability and feasibility of the CBT protocol measured by the Client Satisfaction Questionnaire CBT-PIB

    qualitative and quantitative feedback from participants

    Post-intervention at week 16

  • rates of clinically significant and reliable change in mood measured by the Patient health questionnaire (PHQ-9)

    used to monitor the severity of depression and response to treatment

    Through study completion, an average of 18 weeks

  • rates of clinically significant and reliable change in symptoms of mania measured by the Altman Self-Rating Mania Scale

    scale that assesses the presence and severity of manic or hypomanic symptoms

    Through study completion, an average of 18 weeks

  • Changes in management of impulsivity measured by the Visual Analogue Scale

    Visual scale measuring the severity and impact of general and behavioural impulsivity

    Through study completion, an average of 18 weeks

  • Number of participants with intervention-related adverse events assessed by the adverse events form

    qualitative form eliciting adverse events

    Through study completion, an average of 18 weeks

Secondary Outcomes (5)

  • rates of clinically significant and reliable change in general daily functioning as measured by the Work and Social Adjustment Scale

    At baseline, 2 weeks and 14 weeks

  • rates of clinically significant and reliable change in quality of life as measured by the Brief Quality of Life in Bipolar Disorder

    At baseline, 2 weeks and 14 weeks

  • rates of clinically significant and reliable change in symptoms of anxiety as measured by the General Anxiety Disorder Assessment (GAD7)

    At baseline, in 2 weeks and in 14 weeks

  • rates of clinically significant and reliable change in overall wellbeing as measured by the Warwick-Edinburgh Mental Well-being Scale

    At baseline, in 2 weeks and in 14 weeks

  • rates of clinically significant and reliable change in impulsivity measured by the Short Urgency, Premeditation (lack of), Perseverance (lack of), Sensation Seeking, Positive Urgency, Impulsive Behavior Scale

    At baseline, in 2 weeks and in 14 weeks

Study Arms (1)

CBT for mood driven, problematic, impulsive behaviours

EXPERIMENTAL

All participants will be offered the 12 week CBT intervention

Behavioral: Cognitive Behavioural Therapy for Problematic Impulsive Behaviours

Interventions

Up to 12 sessions of Cognitive Behavioural Therapy adapted to focus on mood-driven impulsivity in adults with bipolar disorder.

CBT for mood driven, problematic, impulsive behaviours

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • meeting diagnostic criteria for Bipolar I or II Disorder (SCID-5- Structured clinical interview for depression )
  • able to identify at least one impulsive, problematic behaviour to target during the intervention;
  • participants will require working knowledge of written and spoken English, sufficient to be able to make use of therapy and to be able complete research assessments without the need of a translator.

You may not qualify if:

  • major depressive episode (identified through SCID-DSM-5);
  • current experience of mania;
  • current/past learning disability (IQ of less than 70 with impairment of social and adaptive functioning)
  • organic brain change or substance dependence (drugs and alcohol) that would compromise ability to use therapy;
  • current marked risk to self (i.e. self-harm or suicide) that we deem could not be appropriately managed in by the therapy site;
  • currently lacking capacity to give informed consent;
  • currently receiving other psychosocial therapy for impulsivity or bipolar disorder;
  • current engagement in another psychological intervention addressing bipolar disorder or impulsivity;
  • presence of another area of difficulty that the therapist and client believe should be the primary focus of intervention (for example, Post-Traumatic Stress Disorder, psychosis).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

AccEPT Clinic

Exeter, Devon, EX4 4QG, United Kingdom

Location

MeSH Terms

Conditions

Impulsive BehaviorBipolar DisorderMania

Interventions

Cognitive Behavioral Therapy

Condition Hierarchy (Ancestors)

BehaviorBipolar and Related DisordersMood DisordersMental DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Behavior TherapyPsychotherapyBehavioral Disciplines and Activities

Study Officials

  • Jan Freeman, MSc

    University of Exeter

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: This project will follow an ABA case-series design. In an ABA design, for an individual receiving a treatment there is a measurement period (baseline) before the treatment phase, and then again after the treatment phase, to allow exploration of the apparent stability of any changes observed over the treatment period. Participants will be assigned to a two-week baseline phase, up to twelve-session intervention phase, and a two-week post-intervention phase. This will allow for three baseline measurements, to establish symptom and mood stability prior to treatment, and a two-week post-intervention measurement phase to explore the stability of any intervention-related changes. Symptoms will be measured weekly across the baseline period, treatment phase and post-treatment periods. Participants will also complete additional self-report measures and be invited to participate in a semi structured interview to gather qualitative feedback post treatment.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 26, 2023

First Posted

November 13, 2023

Study Start

August 17, 2023

Primary Completion (Estimated)

September 10, 2026

Study Completion (Estimated)

January 24, 2027

Last Updated

April 30, 2025

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will share

All data that underlie results in a publication.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
Access will be possible from date of publication.
Access Criteria
The research database will be registered with the University of Exeter public access database. The dataset will be anonymous and will be registered with a metadata only record, allowing the research team to control access to the dataset, restricting it to appropriately qualified third parties.

Locations